Ed Lukins advises clients on capital markets activity and mergers and acquisitions. His clients include UK and overseas public and late stage private companies, entrepreneurs and banks. Ed has advised companies on listings on AIM, NEX and the Main Market and has also advised a large number of non-US companies (or foreign private issuers) on NASDAQ and NYSE IPOs.

Ed's focus is primarily on Capital Markets activity (issuer and underwriter side) and M&A activity (public and private). He also advises on general corporate finance and securities regulatory matters for listed issuers (including the listing rules, MAR and the Takeover Code).

He also has specific knowledge of technology, life sciences and natural resources markets and works extensively on cross-border and international transactions, both transatlantic and across the EMEA region.

As an expert in corporate finance, Ed has spoken widely on these issues and writes in a diverse range of business and academic publications.

  • Ed's experience include advising:

    • National World plc – IPO on the standard segment of the Main Market in the UK, issuer counsel
    • RockRose Energy plc – readmission to the standard segment of the Main Market in the UK following the acquisition of the North Sea interests of US based Marathon Oil
    • OKYO Pharma Limited – IPO on the standard segment of the Main Market in the UK, issuer counsel
    • Tiziana Life Sciences plc – dual listing for an AIM listed life science company on NASDAQ, issuer counsel
    • RenalytxAI plc – IPO on the London AIM market, issuer counsel
    • Endava plc – IPO on the NYSE, issuer counsel
    • Autolus Therapeutics plc – IPO on NASDAQ, issuer counsel
    • Bicycle Therapeutics – IPO on NASDAQ, underwriter counsel
    • Local World Limited – sale to Trinity Mirror plc (now Reach plc)

    Please note: Ed's experience includes that prior to joining Orrick.

Insights

News